FDA Medical Device Product Codes: Analysis of 7,075 Classification Codes

For regulatory affairs (RA) professionals, product developers, and MedTech consultants, the FDA’s medical device classification database is the foundational roadmap for market entry. Every medical device marketed in the United States must map to a specific three-letter Product Code. This code dictates the regulatory class (Class I, II, or III), the applicable regulation number under Title 21 of the Code of Federal Regulations (CFR), the required premarket submission pathway (510(k), PMA, De Novo), and the medical specialty panel responsible for review.

While the FDA's public-facing guides often state that they regulate "about 1,700 generic device types," the actual database of active product codes is far larger and more complex. This article provides a comprehensive structural analysis of the FDA Medical Device Classification Database. Leveraging a recent export containing 7,075 unique product codes, we break down the database by regulatory class, medical specialty panel, Class III concentration, and submission type.

---

Scenario Question & Direct Answer

Question: How many FDA medical device product codes are there, and how do they break down by device class, medical specialty panel, and submission type?

Direct Answer: The openFDA classification database contains 7,075 active product codes. By regulatory class, they split: Class II 3,624 (51.2%), Class I 2,401 (33.9%), and Class III 530 (7.5%), with 383 unclassified (N), 86 unknown (U), and 51 other. Most codes route to the 510(k) pathway (submission_type_id 1 = 3,205 codes; and type 4 = 2,638 codes), while PMA-type codes (type 2) number 500. The largest panels (excluding "Unknown") are Gastroenterology/Urology (563), General & Plastic Surgery (553), Clinical Chemistry (527), and Microbiology (509); the Class III-heaviest panels are Obstetrics/Gynecology (8.63% Class III), Orthopedic (8.00%), and Cardiovascular (5.23%).

---

The Product Code vs. Regulation Number Distinction

To navigate this database, one must first understand a key structural concept: the difference between a Regulation Number (21 CFR Parts 862–892) and a Product Code.

• Regulation Number: The FDA groups devices into approximately 1,700 "generic device types." Each generic type is assigned a regulation number (e.g., 21 CFR 862.1345 for Glucose Test Systems). These regulations define the generic device, its class, and any special controls.
• Product Code: A three-letter code (e.g., QBJ, QLG, LNH) assigned to a specific subtype of device within a regulation number. A single regulation number can contain dozens of product codes. For example, under 21 CFR 862.1345, there are over 10 different product codes separating factory-calibrated CGMs, home-use glucose strips, professional test systems, and multi-analyte monitors.

By analyzing the database at the Product Code level, regulatory teams gain a much more granular view of the competitive landscape and device pathways than is possible by looking only at CFR regulations.

---

Distribution of Product Codes by Regulatory Class

Of the 7,075 active product codes parsed, the distribution by FDA regulatory class is as follows:

• Class II (Moderate Risk): 3,624 codes (51.23%)
• Class I (Low Risk): 2,401 codes (33.94%)
• Class III (High Risk): 530 codes (7.49%)
• Unclassified (N / U / f): 520 codes (7.35%)
  • Class N (Pre-amendment/Not yet classified): 383 codes
  • Class U (Unknown/Other): 86 codes
  • Class f (Unclassified variants): 51 codes

This distribution highlights that over half of all recognized medical device product types are Class II. Class II devices require general controls and, in most cases, a premarket notification under 510(k) clearances by medical specialty panel or compliance with special controls.

Class I devices represent approximately one-third of the database. Most of these are exempt from premarket review, although a subset must still submit 510(k) notifications under specific circumstances. For guidance on navigating these exemptions, see our article on 510(k) exempt product codes and duties.

Class III devices represent a small minority (7.49%). These represent high-risk, life-supporting, or life-sustaining devices, which typically require a Premarket Approval (PMA) application.

---

Recommended Reading

Medical Device Startup Regulatory Strategy: From Concept to FDA Clearance (2026)

Regulatory 510(k)2026-04-13 · 19 min read

Medical Specialty Panels and CFR Parts Mapping

The FDA's classification framework is built around roughly 16 medical specialty panels under 21 CFR Parts 862–892; the openFDA export resolves these into 20 named specialty panels plus a large "Unknown" bucket. Each panel maps to a specific part under Title 21 of the CFR.

Below is a detailed review of these panels, their CFR parts, and their code profiles:

1. In Vitro Diagnostics (IVD) Panels

• Clinical Chemistry (21 CFR Part 862): 527 codes. This panel contains zero Class III codes. Devices here are primarily Class II (453) or Class I (74), covering clinical laboratory test systems (such as glucose assays and lipid panels).
• Clinical Toxicology (21 CFR Part 862): 268 codes. Contains zero Class III codes. Covers drug-of-abuse screens and chemical toxicology assays.
• Immunology (21 CFR Part 866): 289 codes. Contains zero Class III codes. Covers autoimmune disease assays and allergen tests.
• Microbiology (21 CFR Part 866): 509 codes. Includes 3 Class III codes. The vast majority of molecular assays and bacterial culture media are Class II (470) or Class I (36).
• Hematology (21 CFR Part 864): 387 codes. Includes 11 Class III codes. Covers coagulation analyzers, cell counters, and pathology staining reagents.
• Medical Genetics (21 CFR Parts 862–866): 7 codes. A small, cross-panel category covering molecular cytogenetics and next-generation sequencing genotyping assays (for example, HIV-1 genotyping). All seven codes are Class II with zero Class III entries.

2. Clinical and Surgical Specialties

• Gastroenterology, Urology (21 CFR Part 876): 563 codes. Holds 10 Class III codes. This is the largest specialty panel by code count. Devices include endoscopes, urinary catheters, and dialyzers.
• General, Plastic Surgery (21 CFR Part 878): 553 codes. Holds 9 Class III codes. Covers surgical drapes, wound dressings, sutures, and surgical lasers.
• Cardiovascular (21 CFR Part 870): 344 codes. Holds 18 Class III codes. Covers high-risk interventional devices, pacemakers, stents, and ECG monitors.
• Dental (21 CFR Part 872): 328 codes. Holds 14 Class III codes. Covers dental implants, bone grafting materials, and orthodontic brackets.
• General Hospital (21 CFR Part 880): 321 codes. Holds 1 Class III code. Covers syringes, infusion pumps, patient beds, and sterilizers.
• Ophthalmic (21 CFR Part 886): 310 codes. Holds 15 Class III codes. Covers contact lenses, intraocular lenses, and ophthalmic lasers.
• Orthopedic (21 CFR Part 888): 275 codes. Holds 22 Class III codes. One of the highest concentrations of Class III devices, covering total joint replacements and spinal fusion implants.
• Obstetrics/Gynecology (21 CFR Part 884): 255 codes. Holds 22 Class III codes. Tied with Orthopedics for the absolute count of Class III codes, covering fetal monitors, contraceptive implants, and assisted reproduction devices.
• Ear, Nose, Throat (21 CFR Part 874): 235 codes. Holds 2 Class III codes. Covers hearing aids, tympanostomy tubes, and sinus scopes.
• Anesthesiology (21 CFR Part 868): 229 codes. Holds 3 Class III codes. Covers ventilators, anesthesia machines, and airway tubes.
• Neurology (21 CFR Part 882): 228 codes. Holds 11 Class III codes. Covers EEG monitors, intracranial pressure sensors, and neurostimulators.
• Physical Medicine (21 CFR Part 890): 220 codes. Holds 3 Class III codes. Covers wheelchairs, muscle stimulators, and prosthetics.
• Radiology (21 CFR Part 892): 199 codes. Holds 1 Class III code. Covers CT scanners, MRI systems, and diagnostic software.
• Pathology (21 CFR Part 881): 127 codes. Contains zero Class III codes. Covers slide preparation systems and histology tissue processors.

---

The "Unknown" Category: Unclassified & Pre-Amendment Devices

A critical finding for regulatory intelligence is the presence of 901 product codes categorized under the "Unknown" specialty panel.

This category has a massive Class III concentration of 42.73% (385 codes).

Why Does This Category Exist?

This bucket primarily contains:

1. Pre-Amendment Class III Devices: Under Section 515 of the Food, Drug, and Cosmetic Act, devices that were on the market prior to May 28, 1976 (pre-amendment devices) were placed in Class III. Many of these have not been officially transitioned to a specific specialty panel because they are awaiting a formal reclassification rule or a call for PMAs.
2. Novel / Transitional Devices: When a device utilizes a completely new technology that spans multiple medical panels, the FDA may assign it a temporary transitional product code under the "Unknown" category during the De Novo or PMA process until a formal panel classification is established.
3. Combination Products: Devices integrated with drug or biologic components (e.g., drug-eluting beads) that are reviewed by intercenter committees often reside in this unclassified bucket due to their hybrid jurisdiction.

---

Class III Concentration: High-Risk Specialties

For manufacturers considering entering a new medical specialty, understanding the Class III concentration is vital. A high concentration of Class III codes indicates that the specialty is dominated by high-risk, clinically complex technologies where the barrier to entry is high (PMA required).

Excluding the "Unknown" bucket, the panels with the highest concentration of Class III product codes (among panels with 30+ total codes) are:

1. Obstetrics/Gynecology: 8.63% (22 Class III codes out of 255)
2. Orthopedic: 8.00% (22 Class III codes out of 275)
3. Cardiovascular: 5.23% (18 Class III codes out of 344)
4. Ophthalmic: 4.84% (15 Class III codes out of 310)
5. Neurology: 4.82% (11 Class III codes out of 228)
6. Dental: 4.27% (14 Class III codes out of 328)

These panels represent fields where implantable biomaterials, life-sustaining monitors, and complex surgical systems are common. Obstetrics/Gynecology leads due to the regulation of high-risk contraceptive implants, fetal monitors, and assisted reproduction devices. Orthopedics follows closely due to the classification of joint replacements and spinal fusion implants. To compare this with actual clearance and approval trends, see our analysis of the FDA PMA Class III high-risk device landscape.

---

Recommended Reading

FDA Heart Valve Recalls: Edwards, Medtronic & Abbott MAUDE Teardown

Regulatory Post-Market Surveillance2026-07-13 · 18 min read

Submission Types: How Product Codes Route to Market

The database assigns a submission_type_id to each product code, indicating the primary regulatory pathway.

Our parsing of these IDs across the 7,075 product codes yields the following routing map:

• 510(k) Pathway (Type 1): 3,205 codes (45.30%)
• 510(k)-Related / Exempt Variants (Type 4): 2,638 codes (37.29%)
• PMA Pathway (Type 2): 500 codes (7.07%)
• De Novo / Novel Classification (Type 7): 306 codes (4.33%)
• HDE / Humanitarian Device Exemption (Type 3): 113 codes (1.60%)
• PMA-Related / Supplements (Type 6): 57 codes (0.81%)
• Other/Not Specified: 256 codes (3.60%)

This routing map demonstrates that over 82% of all medical device product codes (Types 1 and 4 combined) route through the 510(k) or 510(k)-related framework.

The De Novo pathway (Type 7) has grown to encompass 306 active product codes. The De Novo process is a critical tool for novel, low-to-moderate risk devices that have no existing predicate device. When a De Novo request is granted, the FDA creates a brand-new regulation number and a new product code, which subsequent manufacturers can then use as a predicate for standard 510(k) submissions. For historical De Novo trends, read our FDA De Novo classification database grants analysis.

---

Pathway Economics: MDUFA User Fees and Timelines

Choosing a product code and its corresponding pathway has significant financial and operational implications for manufacturers. Under the Medical Device User Fee Amendments (MDUFA V), the FDA charges substantial fees to review premarket submissions. The figures below are the official FY 2026 rates (October 1, 2025 – September 30, 2026):

• PMA (Type 2): Standard fee is $579,272 (small business fee of $144,818). The FDA’s statutory target review timeline is 180 days, but total decision times regularly run far longer due to multiple rounds of questions, additional data requests, and manufacturing facility inspections.
• De Novo (Type 7): Standard fee is $173,782 (small business fee of $43,446). The target review timeline is 150 review days, with total elapsed time typically extending well beyond that.
• 510(k) (Type 1): Standard fee is $26,067 (small business fee of $6,517). The MDUFA performance target is 90 review days, with average time to clearance running roughly 120–150 elapsed days.

MDUFA Small Business Exemption Rules

To mitigate the high cost of market entry for startups, the FDA provides a Small Business Determination (SBD) program:

• Definition: A company qualifies as a small business if its gross receipts and sales (including affiliates) do not exceed $100 million for the most recent tax year.
• Exemption: First-time premarket approval (PMA) applications are entirely free (100% waiver) for qualified small businesses with gross receipts under $30 million. Subsequent PMAs and De Novo applications receive a reduced small-business fee, and 510(k) submissions are discounted to $6,517 for small businesses.

Additionally, the FDA charges an annual establishment registration fee of $11,423 for FY 2026 for every registered manufacturing facility. Historically this registration fee has had no small-business discount; FY 2026 introduced a limited financial-hardship waiver available to certain qualifying small businesses, but in practice every registered facility should expect to pay this flat annual fee.

This economic structure explains why manufacturers aggressively seek product codes that route through the 510(k) pathway (Type 1 or Type 4). Transitioning a device from a 510(k) to a PMA pathway can multiply regulatory costs by more than 20-fold and delay market entry by over a year.

---

Step-by-Step Regulatory Classification Workflow

When developing a new medical device, regulatory affairs teams should follow this structured workflow to classify their device and identify their product code:

Step 1: Search the Classification Database

• Access the FDA's medical device classification database.
• Input keywords related to the device’s technology and intended use (e.g., "glucose sensor," "electrosurgical").
• Identify all candidate three-letter product codes and their associated regulation numbers.

Step 2: Compare Intended Use and Technology

• Read the official "Device Class" and "Definition" field for each candidate product code.
• Verify if the technological characteristics (e.g., laser wavelength, sensor chemistry) and intended patient population match your device.
• If a candidate code matches, check its submission_type_id to determine the regulatory pathway (e.g., Type 1 indicates a 510(k) is required).

Step 3: Analyze Predicate and Special Controls

• If the device is Class II (Type 1), identify existing cleared devices under that product code to serve as predicates.
• Check if there are active FDA Guidance Documents or special controls listed under the regulation number. Compliance with these guidance documents is mandatory for 510(k) clearance.

Step 4: Determine the De Novo Route

• If no existing product code matches your device's technology or intended use (meaning there is no predicate), determine if the device is low-to-moderate risk.
• If the risk profile is moderate or low, prepare a De Novo request (Type 7) to establish a new product code.
• If the risk profile is high, prepare for a Premarket Approval (PMA, Type 2) pathway.

Step 5: Leverage the 513(g) Process

• If the classification database search is ambiguous or if there is a dispute regarding whether your device is a Class II or Class III, submit a formal 513(g) Request for Information.
• The FDA will review the request and provide a formal, written classification opinion, indicating the class, regulation number, and applicable submission type.

---

Recommended Reading

PMA vs 510(k): Differences, Requirements, and How to Choose the Right FDA Pathway

Regulatory 510(k)2026-03-25 · 83 min read

Data Integrity and Code Maintenance Challenges in openFDA

While the classification database is an invaluable tool, regulatory intelligence professionals must navigate several data integrity challenges:

1. Stale Regulation Numbers: Approximately 3.6% of product codes in the active export reference regulation numbers that have been retired or replaced. RA teams must cross-reference regulation numbers against the current Electronic Code of Federal Regulations (eCFR).
2. Duplicate/Overlapping Code Definitions: Over time, different FDA review branches have established product codes that have overlapping technological definitions. For example, similar software algorithms in radiology can fall under different codes depending on whether they are classified as computer-aided detection (CADe) or computer-aided triage (CADt).
3. The "Unknown" Specialty Bucket: As highlighted in our panel analysis, the 901 codes in the "Unknown" specialty category represent a major documentation gap, requiring manual cross-referencing against primary PMA and De Novo approval notices to identify the historical review panel.

---

Actionable Strategy for Regulatory Teams

When planning a medical device development pipeline, regulatory affairs teams should use these database insights to:

1. Verify Granular Product Codes: Never assume a device class based solely on the regulation number. Always drill down to the specific three-letter product code to check the exact submission_type_id and Class designation.
2. Leverage De Novo for Novel Features: If your device introduces software features or hardware components with no direct predicate, plan for a De Novo pathway. Note that the De Novo pipeline has successfully established 306 active product codes in the database, proving it is a viable and increasingly structured route.
3. Budget for Panel-Specific Timelines: Panels with high Class III concentrations (like Orthopedics or Obstetrics/Gynecology) have highly structured, data-heavy review teams. Anticipate longer review cycles and prepare for potential Advisory Committee meetings, even if your device is a Class II 510(k).

---

Frequently Asked Questions (FAQs)

How many Class III medical device product codes are there in the FDA database?

There are 530 product codes classified as Class III in the openFDA database. Of those 530, roughly 385 sit in the "Unknown" specialty bucket — pre-amendment or not-yet-paneled devices awaiting formal panel assignment — while the remaining ~145 are distributed across named specialty panels (Orthopedics, Obstetrics/Gynecology, and Cardiovascular carry the most).

Which FDA medical specialty panel has the most product codes?

Excluding the "Unknown" category (901 codes), the Gastroenterology/Urology panel has the most product codes with 563 codes, followed closely by the General & Plastic Surgery panel with 553 codes.

How many product codes are unclassified or pre-amendment?

There are 383 unclassified (Class N) product codes in the database. These are devices that were marketed prior to the Medical Device Amendments of 1976 and have not yet been formally classified by the FDA.

What is the 513(g) process?

The 513(g) process is a formal request program where a manufacturer submits details about their device's technology and intended use to the FDA, and the agency returns a formal, written classification opinion.

What does submission_type_id 1 indicate in the classification database?

A submission_type_id of 1 indicates that the product code primarily routes through the premarket notification 510(k) pathway.

What is the difference between a pre-amendment and post-amendment device?

A pre-amendment device is any medical device marketed in the United States prior to the enactment of the Medical Device Amendments on May 28, 1976. Post-amendment devices are those introduced after this date and are subject to contemporary premarket notification or approval pathways.

How does a manufacturer apply for MDUFA small business status?

Manufacturers must submit a formal Small Business Determination (SBD) request to the FDA, including tax returns for the most recent year, before submitting their premarket applications to qualify for the fee reductions.

Are annual facility registration fees discountable for small businesses?

Historically, no. The annual FDA establishment registration fee ($11,423 for FY 2026) has been a flat fee with no standard small-business discount. FY 2026 introduced a limited financial-hardship waiver for certain qualifying small businesses, but most registered facilities should expect to pay the full flat annual fee.